Cagrilintide: The Complete Guide to the Amylin Analog
Cagrilintide is an analog of amylin, a satiety hormone secreted alongside insulin. Developed by Novo Nordisk, it is best known for its combination with semaglutide, CagriSema. Here's what it is, what trials have measured, the current status of its approval, and what remains to be demonstrated.
What is cagrilintide?
Cagrilintide is a synthetic peptide designed by Novo Nordisk to mimic amylin. It was initially designated by the code name AM833. A fatty acid chain attached to the molecule slows its elimination: its half-life exceeds six days, which allowed it to be tested with one injection per week in trials.
- One laboratory: Novo Nordisk, which also produces semaglutide. Cagrilintide does not belong to Eli Lilly, which is developing eloralintide.
- A different pathway from GLP-1 : it does not act on the GLP-1 receptor, but on those of amylin and calcitonin.
- No authorization : it is not authorized as a drug in any country. Only its combination with semaglutide is under review in the United States.
Amylin, the hormone it mimics
Amylin is a peptide of 37 amino acids, secreted by the pancreas along with insulin after meals. It slows gastric emptying, inhibits glucagon secretion, and sends a satiety signal to the brain. Human amylin is not well-suited to long-term research: it aggregates easily and its action is very short-lived. A first analog, pramlintide (Symlin), was approved in the United States in 2005 for diabetes, but it has a short duration of action and is injected before each meal.
How does cagrilintide work?
Cagrilintide activates both amylin and calcitonin receptors, with little selectivity between them. For this reason, researchers classify it among the dual amylin and calcitonin agonists, known as DACRAs. These receptors are located in the brainstem, an area involved in appetite control.
- Satiety : the signal sent to the brain reduces the amount of food consumed.
- Gastric emptying : food leaves the stomach more slowly.
- Glucagon : its secretion decreases after meals.
Semaglutide acts via a different pathway, the GLP-1 receptor. This is why Novo Nordisk combined the two molecules: their effects on weight are additive. In mice, the effect of cagrilintide on weight depends on two subtypes of amylin receptors (Carvas et al., 2025).
What the trials show
Cagrilintide alone, without semaglutide, was tested in two trials, the results of which are published. Weight loss is expressed as a percentage of starting weight.
| Trial | Participants | Duration | Weight loss | Placebo |
|---|---|---|---|---|
| Phase 2 (Lau et al., 2021) | 706 | 26 weeks | Up to 10.8% (highest dose) | 3,0 % |
| Phase 3, REDEFINE 1 (cagrilintide group alone) | One of the four groups (3,417 in total) | 68 weeks | 11,5 % | 3,0 % |
| Phase 3, RENEW 1 and 2 | Approximately 630 | 64 weeks | No results yet | – |
In the phase 2 trial, the highest dose performed slightly better than liraglutide, an already approved GLP-1 analog: 10.8% versus 9.0%. In phase 3, cagrilintide alone (11.5%) performed worse than semaglutide alone (14.9%) and significantly worse than the combination of the two (20.4%). Novo Nordisk launched a phase 3 program for cagrilintide alone, RENEW, in November 2025, with the first two trials scheduled for completion in May 2027.
CagriSema, the combination with semaglutide
Most of the data on cagrilintide comes from CagriSema, which combines the two molecules in a weekly injection. In the REDEFINE 1 trial, conducted over 68 weeks in 3,417 overweight or obese adults without diabetes, weight loss reached 20.4%, compared to 3.0% with placebo. However, CagriSema has not demonstrated that it performs at least as well as tirzepatide. The results, trial by trial, and the status of the marketing authorization application are detailed on our page dedicated to CagriSema. The comparison with Eli Lilly's triple agonist is on the page retatrutide vs cagrilintide.
Other amylin analogues
| Molecule | Laboratory | Special feature | Status |
|---|---|---|---|
| Pramlintide (Symlin) | – | Short action, before each meal | Approved in the United States since 2005 (diabetes) |
| Cagrilintide | Novo Nordisk | Long-acting, one injection per week in trials | Phase 3 |
| Eloralintide | Eli Lilly | Long-acting amylin agonist | Phase 3 |
Other molecules in this family are under development, such as petrelintide from Zealand Pharma, or amycretin from Novo Nordisk, which combines the actions of GLP-1 and amylin in a single molecule. Our article on eloralintide compares the two most advanced analogs.
Status of cagrilintide in 2026
Cagrilintide is not authorized as a medication in any country. In the United States, the FDA reiterates that it cannot be used in compounded preparations, as it is not an ingredient in any authorized medication. CagriSema was submitted to the FDA in December 2025, and a decision is expected by the end of 2026. To our knowledge, no application to the European Medicines Agency has been publicly announced. Finally, the World Anti-Doping Agency permanently prohibits substances that do not have marketing authorization, including cagrilintide.
- Name : cagrilintide (International Nonproprietary Name, INN), code names AM833 and NNC0174-0833.
- Class : acylated analogue of amylin, agonist of amylin and calcitonin receptors.
- Molecule : 4409 g/mol, formula and CAS number on the page COA and technical specifications.
Price of cagrilintide at MyPeptide
The 5 mg vial costs €69.90. The current batch, MP-777CG101, was analyzed by the Janoshik laboratory: 99.836% purity and 4.92 mg measured for the advertised 5 mg. Prices vary considerably between sellers. To compare two offers, compare the price per milligram and verify that the seller publishes the report for the batch being sold, along with a verification key. Bacteriostatic water is used for reconstitution.
One 5 mg lyophilized vial. Batch MP-777CG101 analyzed by Janoshik: purity 99.836%, 4.92 mg measured. Shipping from the European Union in 2 to 5 business days; delivery €10, free from €160.
Cagrilintide 5 mg – €69.90
- CagriSema: trials and authorization
- Side effects and safety
- Our Janoshik (COA) analysis
- Retatrutide vs cagrilintide
- The mechanisms of amylin (article)
Frequently asked questions
What is cagrilintide?
An analogue of amylin, the satiety hormone secreted with insulin. Developed by Novo Nordisk under the code name AM833, it acts on amylin and calcitonin receptors. It is not authorized as a medicine in any country.
Is cagrilintide a GLP-1?
No. It acts on amylin and calcitonin receptors, not on the GLP-1 receptor. That is why Novo Nordisk combines it with semaglutide, a GLP-1 analogue, in CagriSema.
Is cagrilintide a product of Eli Lilly?
No, it is developed by Novo Nordisk. Eli Lilly's amylin analogue is called eloralintide.
What weight loss can be expected with cagrilintide alone?
Up to 10.8% in 26 weeks in the phase 2 trial, versus 3.0% on placebo, and 11.5% in 68 weeks in the cagrilintide-only group of the REDEFINE 1 trial.
Is cagrilintide authorized in France?
No. It is not authorized as a drug in any country. Its combination with semaglutide, CagriSema, is under review in the United States.
What dosage should be used for cagrilintide?
MyPeptide does not provide dosage or protocol information. Our products are intended exclusively for scientific laboratory research.
Sources: Lau D.C.W. et al., Lancet 2021; Garvey W.T. et al., N Engl J Med 2025 (REDEFINE 1); Enebo L.B. et al., Lancet 2021; Kruse T. et al., J Med Chem 2021; Hay D.L. et al., Pharmacol Rev 2015; Carvas A.O. et al., EBioMedicine 2025; ClinicalTrials.gov (RENEW 1 and 2); FDA, page on unapproved GLP-1s (01/10/2026); World Anti-Doping Agency, 2026 list. MyPeptide products are intended for scientific laboratory research use only.
